AML1/ETO, a promiscuous fusion oncoprotein

Blood

Volumn 109, Issue 10, 2007, Pages 4109-4110

  Petrie, Kevin ^a   Zelent, Arthur ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; HYBRID PROTEIN; ONCOPROTEIN; RETINOIC ACID RECEPTOR ALPHA; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; CELL DIFFERENTIATION; CELL RENEWAL; DNA BINDING; DNA METHYLATION; DRUG INHIBITION; GENE SILENCING; GENE TARGETING; GENE TRANSLOCATION; HEMATOPOIESIS; HUMAN; LEUKEMOGENESIS; NONHUMAN; NOTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CONFORMATION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

EID: 34248327966     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-02-075804     Document Type: Note

References (5)

1. Elagib KE, Goldfarb AN. Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation. Cancer Lett. Prepublished on November 27, 2006, as DOI 10.1016/j.canlet.2006.10.010.
2. Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000;14:121-141.
3. Purton LE, Dworkin S, Olsen GH, et al. RARgamma is critical for maintaining a balance between hematopoietic stem cell self-renewal and differentiation. J Exp Med. 2006;203:1283-1293.
4. Zhou GB, Kang H, Wang L, et al. Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo. Blood. Prepublished on December 29, 2006, as DOI 10.1182/blood-2006-06-032250.
5. Zelent A, Petrie K, Lotan R, Waxman S, Gore SD. Clinical translation of epigenetics in cancer: eN-CORe, a report on the second workshop. Mol Cancer Ther. 2005;4:1810-1819.